Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer

Histopathology

Volumn 51, Issue 1, 2007, Pages 40-53

  Song, J ^a   Bai, J ^a   Yang, W ^a   Gabrielson, E W ^a   Chan, D W ^a   Zhang, Z ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Breast cancer; EBP50; Immunohistochemistry; Oestrogen; RNA in situ hybridization

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; EZRIN; EZRIN RADIXIN MOESIN BINDING PHOSPHOPROTEIN 50; MOESIN; PHOSPHOPROTEIN; RADIXIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; TISSUE MICROARRAY; VALIDATION PROCESS;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; RNA, MESSENGER; SODIUM-HYDROGEN ANTIPORTER; TUMOR MARKERS, BIOLOGICAL;

EID: 34250846034     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02730.x     Document Type: Article

References (38)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J. Clin. 2000 50 7 33.
2. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002 2 101 112.
3. Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl Acad. Sci. USA 1992 89 11538 11542.
4. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat. 1997 44 23 38.
5. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M. How to target estrogen receptor-negative breast cancer? Endocr. Relat. Cancer 2003 10 261 266.
6. Buckhaults P, Zhang Z, Chen YC et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res. 2003 63 4144 4149.
7. Reczek D, Berryman M, Bretscher A. Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J. Cell Biol. 1997 139 169 179.
8. Weinman EJ, Steplock D, Wang Y, Shenolikar S. Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na(+)-H+ exchanger. J. Clin. Invest. 1995 95 2143 2149.
9. Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M. A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor. Nature 1999 401 286 290.
10. Maudsley S, Zamah AM, Rahman N et al. Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol. Cell Biol. 2000 20 8352 8363.
11. Hall RA, Ostedgaard LS, Premont RT et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc. Natl Acad. Sci. USA 1998 95 8496 8501.
12. Short DB, Trotter KW, Reczek D et al. An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J. Biol. Chem. 1998 273 19797 19801.
13. Reczek D, Bretscher A. The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule. J. Biol. Chem. 1998 273 18452 18458.
14. Murthy A, Gonzalez-Agosti C, Cordero E et al. NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem. 1998 273 1273 1276.
15. Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP et al. NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am. J. Pathol. 2001 158 57 62.
16. Fouassier L, Duan CY, Feranchak AP et al. Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology 2001 33 166 176.
17. Morales FC, Takahashi Y, Kreimann EL, Georgescu MM. Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. Proc. Natl Acad. Sci. USA 2004 101 17705 17710.
18. Mullin JM. Epithelial barriers, compartmentation, and cancer. Sci. STKE 2004 pe2.
19. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS. Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology 1999 140 2976 2982.
20. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 2001 10 657 662.
21. Fenton H, Carlile B, Montgomery EA et al. LKB1 protein expression in human breast cancer. Appl. Immunohistochem. Mol. Morph. 2006 14 146 153.
22. Song J, Yang W, Shih Ie M, Zhang Z, Bai J. Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochim. Biophys. Acta 2006 1760 62 69.
23. Armes JE, Trute L, White D et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999 59 2011 2017.
24. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 2001 61 903 907.
25. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 1999 17 1983 1987.
26. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S. EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 2003 38 178 186.
27. Dai JL, Wang L, Sahin AA et al. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 2004 23 8681 8687.
28. Vic P, Vignon F, Derocq D, Rochefort H. Effect of estradiol on the ultrastructure of the MCF7 human breast cancer cells in culture. Cancer Res. 1982 42 667 673.
29. Antakly T, Pelletier G, Zeytinoglu F, Labrie F. Changes of cell morphology and prolactin secretion induced by 2-Br-alpha-ergocryptine, estradiol, and thyrotropin-releasing hormone in rat anterior pituitary cells in culture. J. Cell Biol. 1980 86 377 387.
30. Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod. 1996 54 287 293.
31. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 1993 7 743 752.
32. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 1998 58 627 632.
33. Migliaccio A, Pagano M, Auricchio F. Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 1993 8 2183 2191.
34. Roger P, Sahla ME, Makela S et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001 61 2537 2541.
35. Ali SH, O'Donnell AL, Balu D et al. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res. 2000 60 7094 7098.
36. Lazar CS, Cresson CM, Lauffenburger DA, Gill GN. The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol. Biol. Cell 2004 15 5470 5480.
37. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J. Mol. Med. 1997 75 429 439.
38. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br. J. Cancer 2001 85 869 874.